financetom
Business
financetom
/
Business
/
Meta urges California attorney general to stop OpenAI from becoming for-profit, WSJ reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Meta urges California attorney general to stop OpenAI from becoming for-profit, WSJ reports
Dec 13, 2024 5:25 PM

Dec 13 (Reuters) - Meta Platforms ( META ) is urging

California's attorney general to block OpenAI's planned

conversion to a for-profit company, the Wall Street Journal

reported on Friday.

In a letter to Attorney General Rob Bonta dated Thursday,

Meta said that allowing OpenAI to become a for-profit company

would set a dangerous precedent of allowing startups to enjoy

the advantages of nonprofit status until they are poised to

become profitable, WSJ reported.

"OpenAI's conduct could have seismic implications for

Silicon Valley. If OpenAI's new business model is valid,

non-profit investors would get the same for-profit upside as

those who invest the conventional way in for-profit companies

while also benefiting from tax write-offs bestowed by the

government," the WSJ report quotes Meta as saying in the letter.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exclusive-Synchron, a rival to Musk's Neuralink, readies large-scale brain implant trial
Exclusive-Synchron, a rival to Musk's Neuralink, readies large-scale brain implant trial
Apr 8, 2024
WASHINGTON (Reuters) - Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters. Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants,...
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Apr 8, 2024
06:10 AM EDT, 04/08/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Sunday that a phase 2 study evaluating the investigational drug zilebesiran in treating hypertension has met its primary endpoint. Zilebesiran reached the study's primary endpoint after demonstrating statistically significant reductions in systolic blood pressure in three months, the company said. Most laboratory abnormalities of interest were mild,...
EIA Notes Full Solar Eclipse's Impact On Solar Power Generation
EIA Notes Full Solar Eclipse's Impact On Solar Power Generation
Apr 8, 2024
06:05 AM EDT, 04/08/2024 (MT Newswires) -- A full solar eclipse on Monday will briefly obscure sunlight to utility-scale solar generation facilities from Texas through Maine with a combined 6.5 gigawatts of capacity, the US Energy Information Administration reported Friday. The eclipse will also partially block sunlight to facilities with a combined 84.8 GW of capacity in a larger swath...
Guyana gas-to-power project to shave weeks off oil output, hit revenue
Guyana gas-to-power project to shave weeks off oil output, hit revenue
Apr 8, 2024
GEORGETOWN (Reuters) - Guyana's efforts to use its natural gas resources to fuel a power plant that would slash the South American nation's energy costs have snagged on construction delays and threaten to curtail the rising oil hotspot's revenue this year by about $1 billion. The $1.9 billion gas-to-power project, Guyana's biggest effort to capitalize on its energy bounty, is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved